Japanese guidelines for atopic dermatitis 2020
-
- Katoh Norito
- Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
-
- Ohya Yukihiro
- Allergy Center, National Center for Child Health and Development
-
- Ikeda Masanori
- Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
-
- Ebihara Tamotsu
- Department of Dermatology, Keio University School of Medicine
-
- Katayama Ichiro
- Department of Dermatology, Graduate School of Medicine, Osaka University
-
- Saeki Hidehisa
- Department of Dermatology, Graduate School of Medicine, Nihon Medical School
-
- Shimojo Naoki
- Department of Pediatrics, Graduate School of Medicine, Chiba University
-
- Tanaka Akio
- Department of Dermatology, Hiroshima University Graduate School of Biomedical Sciences
-
- Nakahara Takeshi
- Division of Skin Surface Sensing, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
-
- Nagao Mizuho
- Division of Clinical Research, National Hospital Organization Mie National Hospital
-
- Hide Michihiro
- Department of Dermatology, Hiroshima University Graduate School of Biomedical Sciences
-
- Fujita Yuji
- Department of Pediatrics, Graduate School of Medicine, Chiba University
-
- Fujisawa Takao
- Division of Allergy, National Hospital Organization Mie National Hospital
-
- Futamura Masaki
- Division of Pediatrics, National Hospital Organization Nagoya Medical Center
-
- Masuda Koji
- Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
-
- Murota Hiroyuki
- Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences
-
- Yamamoto-Hanada Kiwako
- Allergy Center, National Center for Child Health and Development
Search this article
Abstract
<p>Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.</p>
Journal
-
- Allergology International
-
Allergology International 69 (3), 356-369, 2020
Japanese Society of Allergology
- Tweet
Details 詳細情報について
-
- CRID
- 1390285300176733184
-
- NII Article ID
- 130007877730
-
- NII Book ID
- AA11091750
-
- ISSN
- 14401592
- 13238930
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- IRDB
- Crossref
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed